Best Pharmaceutical Stocks in India 2022

The Indian pharmaceutical industry was valued at an estimated US$42 billion in 2021.India is the world’s third largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 50% of all vaccines manufactured in the world. Indian exports meet the standards and requirements of highly regulated markets of USA, UK, European Union and Canada.

Also Check: Best Chemical Stocks in India 2022

Sun Pharmaceuticals Industries Ltd

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. From humble beginnings in 1983 with just 2 employees and 5 psychiatry products to becoming the 4th largest global generic pharmaceutical company, selling over 2000 products in over 100 countries. Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck. Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India. The territory of the licensing agreement will only cover India.

Dr Reddys Laboratories Ltd

Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care and biotechnology products. Over the past few years, DRREDDY have been focused on orphan drugs, designed to address the needs of patients suffering from rare diseases. One of the products recently launched in the US goes to treat Wilson’s disease, a genetic disorder that causes excessive copper in the body. Dr. Reddy’s Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market.

Divi’s Laboratories Ltd

Divi’s has been established for more than 30 years in Hyderabad, India with two manufacturing units and is among the top pharmaceuticals companies in India. Divi’s is recognized as a ‘Reliable Supplier of generic APIs (Active pharmaceuticals ingredients)’ and a trustworthy ‘Custom Manufacturer’ to Big Pharma and also is among the top API manufactures in the world. Divi’s is the leading manufacturer of APIs(Active pharmaceuticals ingredients), Intermediates and Registered starting materials offering high quality products with the highest level of compliance and integrity to over 95 countries. reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad .17,000 highly trained professionals across departments and ~500 scientists at Divi’s work together to bring world class products to customers.

Cipla Ltd

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions. It was founded by Khwaja Abdul Hamied as ‘The Chemical, Industrial & Pharmaceutical Laboratories’ in 1935 in Mumbai. The name of the company was changed to ‘Cipla Limited’ on 20 July 1984.In the year 1985, the US FDA approved the company’s bulk drug manufacturing facilities. Led by the founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world. Cipla Foundation takes the company’s socially conscious legacy forward through initiatives in Health, Skilling Education and Environmental Sustainability & Disaster Response.

Biocon Ltd

Biocon Limited is an Indian biopharmaceutical company that is based in Bangalore, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon’s biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research services space. Established in 1993, Syngene International Limited is a contract research and development organization (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients. The company has four divisions: drug discovery services, dedicated research centres, development devices and manufacturing. Biocon on Thursday reported a 4 per cent decline in consolidated net profit to Rs 283.9 crore in the fourth quarter ended.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals. The company commenced operations in 1988-89 with a single unit manufacturing Semi- Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma receives USFDA Approval for Guaifenesin Extended-Release Tablets (OTC) Aurobindo The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin extended-release tablets, 600mg and 1200 mg (OTC). Aurobindo’s Guaifenesin extended-release tablets are the AB rated generic equivalent of RB Health (US) LLC’s Mucinex® tablets. The product is expected to launch in Q4FY20.

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, owned by Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Torrent Pharma blazed a new trail in the Indian Pharmaceuticals industry by successfully implementing the concept of niche marketing. We were the pioneers in initiating the concept of niche marketing and today, is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, genecology, oncology and anti-infective segments.Torrent Pharma also has a strong international presence spread across 40 countries with operations in regulated and emerging markets like US, Europe, Brazil and Rest of the World. The Company operate through its wholly owned subsidiaries spread across 12 nations with major setups in Brazil, Germany and US.